Benzinga - by Vandana Singh, Benzinga Editor.
Monday, the FDA granted 510(k) clearance to Baxter International Inc’s (NYSE:BAX) Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software.
Novum IQ LVP and Novum IQ syringe infusion pump (SYR) infusion pumps share a common user interface to associate a patient, medication, and pump through a digital on-screen barcode.
The pumps streamline the training clinicians need and help reduce the cognitive burden of properly operating multiple disparate pump platforms.
Dose IQ Safety Software features a web-based, customizable drug library and dose error reduction system. Dose IQ supports clinicians and hospitals by helping ensure pumps are up to date with the latest, facility-specific drug and dosage parameters and information through centralized access to current drug library files. In addition, Dose IQ includes exclusive titration error prevention technology designed to provide additional safety measures.
Also Read: Baxter Says 2023 Performance Reflects Strategic Initiatives With New Operating Model Without BioPharma Solutions Unit.
IQ Enterprise Connectivity Suite, a scalable all-in-one server, integration engine, and software application platform, is designed to simplify infusion system connectivity for the Novum IQ Infusion Platform. The IQ Enterprise Suite enables:
- Full bi-directional electronic medical record (EMR) interoperability with auto-programming and auto-documentation capabilities.
- Provides on-demand and actionable graphical views of infusion data at the bedside.
- Over-the-air software updates could help save clinicians time and enhance efficiency for biomedical engineers, who do not need to remove pumps from the nursing floor for manual software and firmware updates.
Baxter’s Novum IQ LVP supports the administration of high-volume infusions at faster rates, while Novum IQ SYR supports the delivery of small, precise amounts of fluid at lower rates, often in pediatric, neonatal, or anesthesia care settings.
Price Action: BAX shares are up 2.23% at $43.69 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.